From Allergy Med to Metabolic Hack | The Amlexanox Breakdown
The Hunter Williams Podcast
How Amlexanox Triggers IL-6→STAT3 and Influences Glycemia
Hunter explains acute adipose IL-6 secretion, hepatic STAT3 activation, and rapid suppression of gluconeogenesis improving blood glucose.
Get My Book On Amazon: https://a.co/d/avbaV48Download
The Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/
Download The Bioregulator Cheat Sheet: https://bioregulatorcheatsheet.carrd.co/
1 On 1 Coaching Application: https://hunterwilliamscoaching.carrd.co/
Book A Call With Me: https://hunterwilliamscall.carrd.co/
Supplement Sources: https://hunterwilliamssupplements.carrd.co/
Amazon Storefront: https://www.amazon.com/shop/hunterwilliams/list/WE16G2223BXA?ref_=cm_sw_r_cp_ud_aipsflist_R7QWQC0P1RACB2ETY3DY
Socials:
Instagram: https://www.instagram.com/hunterwilliamscoaching/Podcast: https://hunterwilliamspodcast.buzzsprout.com/
Video Topic Request: https://hunterwilliamsvideotopic.carrd.co/
In today’s video I unpack amlexanox—an old anti-inflammatory/allergy drug with surprising metabolic effects. I share my first encounter with it in the research-chem world, what I noticed subjectively, and then dive into mechanisms (IKKε/TBK1 inhibition, catecholamine resensitization, beige fat), rodent data, the Phase 2 human trial (150 mg/day), safety, dosing, who seems to respond best, and how I’m stacking it inside Bio Ignite. If your goal is fat loss with stubborn adipose inflammation, this is worth understanding.
0:00 - Welcome + what today’s video covers
0:28 - How I first found “AM Lox” browsing catalogs
1:06 - Cycling off SLU-PP-332 and first personal trial
1:40 - Noticing dryness/ab definition; early under-dosing
2:12 - 2025 “sugar diet” + hunting for FGF21 boosters
2:40 - Finding data that amlexanox increases FGF21
3:02 - Literature dosage (100–150 mg) vs my early dose
3:38 - Why I think it’s a useful fat-loss rotation tool
4:24 - Channel/hosting update + where to find my videos
5:08 - Slides start: what amlexanox is/was used for
6:00 - Core mechanism: IKKε/TBK1 → PDE3B → cAMP resistance
7:16 - IL-6→STAT3 hepatic signaling + beigeing via FGF21
8:30 - Big-picture benefits: inflammation, insulin sensitivity, glycemia
10:32 - Human data: Phase 2 trial (150 mg/day x 12 weeks)
11:10 - Modest/variable weight change; who improved most
12:37 - Practical takeaways: glycemia, liver fat, insulin sensitivity
14:12 - Dosing in practice (50 mg caps, TID = 150 mg/day)
15:12 - Responder phenotype: high adipose inflammation
16:00 - Who benefits most + variability at similar body fat
17:56 - Study roll-up and mechanism recap
18:52 - Final thoughts, use-cases, and product note (Bio Ignite)
19:54 - Thank you + where to grab the peptide cheat sheet
What You'll Learn
Why amlexanox can “release the brakes” on fat-burning by inhibiting IKKε/TBK1 and restoring cAMP/catecholamine responsiveness.
How it raises IL-6 transiently in adipose, activates STAT3 in the liver, suppresses gluconeogenesis, and increases FGF21 to promote beige fat programs.
The mouse vs. human gap: robust fat loss in mice; in humans, clearer improvements in A1c, fructosamine, liver fat, insulin sensitivity—especially when adipose inflammation is high.
Dosing used in the Phase 2 trial: 50 mg TID (total 150 mg/day) for 12 weeks.
Safety snapshot: no serious AEs attributed to amlexanox in metabolic trials; most common was a transient rash.
Timestamps (exact to the transcript)What you’ll learn
The AI-powered Podcast Player
